Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
RXRX Recursion Pharmaceuticals
8.330+0.270+3.35%
Close
01/31 16:00 ET
8.500+0.170+2.04%
Post Mkt Price 01/31 19:35 ET
High
8.460
Open
8.090
Turnover
5.86M
Low
8.090
Pre Close
8.060
Volume
704.55K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 26th. The
Mubadala Investment Co Pjsc Acquires 24,526 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) major shareholder Mubadala Investment Co Pjsc bought 24,526 shares of the business's stock in a transaction that occurred on Wednesday, Janu
DekaBank Deutsche Girozentrale Acquires 21,500 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
DekaBank Deutsche Girozentrale lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 55.8% in the 3rd quarter, according to the company in its most recent filing with
Shareholders in Recursion Pharmaceuticals (NASDAQ:RXRX) Have Lost 24%, as Stock Drops 5.3% This Past Week
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders should be happy to see the share price up 14% in the last month. But that is minimal compensation for the share price under-performance ov
Blake Borgeson Sells 8,885 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the business's stock in a transaction that occurred on Tuesday, January 24th. The stock was sol
Recursion Pharmaceuticals Releases Compound Intelligence Tool for Drug Discovery, Cellular Imaging Dataset
11:53 AM EST, 01/26/2023 (MT Newswires) -- Recursion Pharmaceuticals (RXRX) said Thursday it released MolRec, a compound intelligence tool for drug discovery, along with RXRX3, its largest open-source
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating
09:52 AM EST, 01/23/2023 (MT Newswires) -- SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating Price: 8.49, Change: -0.16, Percent Change: -
SVB Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
Company Overview
More
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
CEO： Dr. Christopher Gibson, PhD
Market： NASDAQ
Listing Date： 04/16/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet